Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells.

ABSTRACT: Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all patients respond to the treatment. Retinoic acid (RA) has been proposed as an adjuvant treatment of breast carcinoma because of its ability to inhibit cell growth. We evaluated the effect of Tz in combination with RA on the viability, adhesion, migration, invasion and expression of migration-related proteins in SKBR3 and BT-474 human breast cancer cells. MTT, pharmacological interaction analysis, immunofluorescence, adhesion/migration/invasion and Western blot assays were performed. The coadmin

SUBMITTER: Vanderhoeven F 

PROVIDER: S-EPMC5995169 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature